Literature DB >> 1184755

Glucagon regulation of plasma ketone body concentration in human diabetes.

D S Schade, R P Eaton.   

Abstract

The present study was designed to test the hypothesis that physiological concentrations of glucagon may increase plasma ketone body concentration when sufficient free fatty acid substrate is available to support hepatic ketogenesis. Physiological elevations of plasma glucagon concentration were produced by a constant infusion of hormone, and increased plasma-free fatty acid availability was produced by simultaneous heparin injection to induce intravascular lipolysis. In the five insulin-dependent subjects studied, when plasma glucagon concentration remained at the normal basal level of 72+/-14 pg/ml during control saline infusion, the heparin-induced increase in free fatty acid availability resulted in approximately a 20% increase in plasma ketone body concentration. In contrast, when plasma glucagon concentration was elevated by hormone infusion to the physiological level of 215+/-35 pg/ml, the heparin-induced increases in free fatty acid availability resulted in approximately an 80% increase in plasma ketone body concentration. These results suggest that physiological elevations in plasma glucagon concentration may augment ketonemia in diabetic man when simultaneous elevations in plasma-free fatty acid arepresent.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184755      PMCID: PMC301999          DOI: 10.1172/JCI108212

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  12 in total

1.  Plasma glucagon and alanine responses to acute insulin deficiency in man.

Authors:  J E Gerich; E Tsalikian; M Lorenzi; J H Karam; D M Bier
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

2.  A simple method for the determination of serum free insulin levels in insulin-treated patients.

Authors:  S Nakagawa; H Nakayama; T Sasaki; K Yoshino; Y Y Yu
Journal:  Diabetes       Date:  1973-08       Impact factor: 9.461

3.  The effects of glucagon, dibutyryl cyclic adenosine 3',5'-monophosphate, and concentration of free fatty acid on hepatic lipid metabolism.

Authors:  M Heimberg; I Weinstein; M Kohout
Journal:  J Biol Chem       Date:  1969-10-10       Impact factor: 5.157

4.  Liver and kidney metabolism during prolonged starvation.

Authors:  O E Owen; P Felig; A P Morgan; J Wahren; G F Cahill
Journal:  J Clin Invest       Date:  1969-03       Impact factor: 14.808

Review 5.  Regulation of ketogenesis and clinical aspects of the ketotic state.

Authors:  J D McGarry; D W Foster
Journal:  Metabolism       Date:  1972-05       Impact factor: 8.694

6.  Modulation of fatty acid metabolism by glucagon in man. I. Effects in normal subjects.

Authors:  D S Schade; R P Eaton
Journal:  Diabetes       Date:  1975-05       Impact factor: 9.461

7.  Effects of alternations of plasma free fatty acid levels on pancreatic glucagon secretion in man.

Authors:  J E Gerich; M Langlois; V Schneider; J H Karam; C Noacco
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

8.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.

Authors:  J E Gerich; M Lorenzi; D M Bier; V Schneider; E Tsalikian; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

9.  Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men.

Authors:  J E Liljenquist; J D Bomboy; S B Lewis; B C Sinclair-Smith; P W Felts; W W Lacy; O B Crofford; G W Liddle
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  Role of glucagon and other hormones in development of diabetic ketoacidosis.

Authors:  K G Alberti
Journal:  Lancet       Date:  1975-06-14       Impact factor: 79.321

View more
  10 in total

Review 1.  Diabetic ketoacidosis.

Authors:  D G Patel; S C Kalhan
Journal:  Indian J Pediatr       Date:  1986 Sep-Oct       Impact factor: 1.967

Review 2.  Lipoatrophic diabetes.

Authors:  H Dörfler; G Rauh; R Bassermann
Journal:  Clin Investig       Date:  1993-04

3.  Effects of exogenous glucagon and epinephrine in physiological amounts on the blood levels of free fatty acids and glycerol in dogs.

Authors:  W A Muller; T T Aoki; R H Egdahl; G F Cahill
Journal:  Diabetologia       Date:  1977-01       Impact factor: 10.122

4.  The metabolic response to norepinephrine in normal versus diabetic man.

Authors:  D S Schade; R P Eaton
Journal:  Diabetologia       Date:  1978-12       Impact factor: 10.122

5.  Failure of glucagon to stimulate ketone body production during acute insulin deficiency or insulin replacement in man.

Authors:  G E Sonnenberg; W Stauffacher; U Keller
Journal:  Diabetologia       Date:  1982-08       Impact factor: 10.122

6.  The role of "diabetogenic" hormones on carbohydrate and lipid metabolism following oral glucose loading in insulin dependent diabetics: effects of acute hormone administration.

Authors:  P Bratusch-Marrain; W Waldhäusl; B Grubeck-Loebenstein; A Korn; H Vierhapper; P Nowotny
Journal:  Diabetologia       Date:  1981-10       Impact factor: 10.122

7.  Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man.

Authors:  J M Miles; M W Haymond; S L Nissen; J E Gerich
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

8.  Effects of acetylsalicylic acid on plasma glucose, free fatty acid, betahydroxybutyrate, glucagon and C-peptide responses to salbutamol in insulin-dependent diabetic subjects.

Authors:  D Giugliano; N Passariello; R Torella; T Cerciello; M Varricchio; S Sgambato
Journal:  Acta Diabetol Lat       Date:  1981

9.  Effect of a somatostatin analog on insulin requirement and hormone levels in 6 insulin-dependent juvenile-onset diabetics subjected to artificial pancreas.

Authors:  G Lenti; M Trovati; R Lorenzati; F Vitelli; V Tagliaferro; A Marocco; G Pagano
Journal:  Acta Diabetol Lat       Date:  1980 Jan-Mar

Review 10.  Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors.

Authors:  Sarayut Lahnwong; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cardiovasc Diabetol       Date:  2018-07-10       Impact factor: 9.951

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.